British sprinter Levine provisionally suspended over failed drugs test

Updated: Feb 07, 2018, 17:41 IST | AFP

British sprinter Nigel Levine has been provisionally suspended after failing a drugs test, UK Athletics announced on Wednesday. It was reported in December that the 28-year-old had allegedly tested positive for the banned asthma drug clenbuterol

Representational Pic

British sprinter Nigel Levine has been provisionally suspended after failing a drugs test, UK Athletics announced on Wednesday. It was reported in December that the 28-year-old had allegedly tested positive for the banned asthma drug clenbuterol.

The European 4x400 metres gold medallist, who was born in born in Trinidad and Tobago, failed the test while recovering from career-threatening injuries suffered in a motorbike accident last January.

"UK Athletics has today announced that athlete Nigel Levine has been provisionally suspended from participating in athletics after being charged with having committed an anti-doping rule violation contrary to IAAF anti-doping rule article 2.1 (presence of a prohibited substance or its metabolites or markers in an athlete's sample)," said a statement from UK Athletics.

"The provisional suspension was issued by UK Anti-Doping and is in accordance with IAAF anti-doping rules. "The individual now has the opportunity to respond to the charge against him including the right to a full hearing of the case." Clenbuterol is a performance-enhancing substance banned by the World Anti-Doping Agency (WADA).

Catch up on all the latest sports news and updates here

Download the new mid-day Android and iOS apps to get updates on all the latest and trending stories on the go

Trending Video

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
Loading...

Ravi Shastri re-appointed as Team India head coach

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK